San Diego Blood Chip Maker BioFluidica Awarded Two NIH/NCI Grants for Isolation of Cell-Free DNA and Exosomes on Its Single Liquid Biopsy Platform

PR Newswire, January 07, 2019 SAN DIEGO /PRNewswire/ -- BioFluidica, a privately held cancer diagnostics company, has been awarded two separate SBIR Phase I NIH grants, the first [Read More...]

San Diego Blood Chip Maker BioFluidica Awarded Two NIH/NCI Grants for Isolation of Cell-Free DNA and Exosomes on Its Single Liquid Biopsy Platform2022-11-03T10:15:18-07:00

In Promise of True Liquid Biopsy for Cancer, BioFluidica® Launches Human Trial for Rapid Detection of Minimal Residual Disease in Acute Myeloid Leukemia from Peripheral Blood Using high through-put automation and programmable Microfluidic Chips

PR Newswire, May 19, 2018 SAN DIEGO /PRNewswire/ -- BioFluidica, a privately held cancer diagnostics company, today announced the continuation of a highly successful small patient study [Read More...]

In Promise of True Liquid Biopsy for Cancer, BioFluidica® Launches Human Trial for Rapid Detection of Minimal Residual Disease in Acute Myeloid Leukemia from Peripheral Blood Using high through-put automation and programmable Microfluidic Chips2022-11-03T10:16:40-07:00
Go to Top